Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 21-26

  Stevens, Kirk L ^a   Alligood, Krystal J ^a   Alberti, Jennifer G Badiang ^a   Caferro, Thomas R ^a   Chamberlain, Stanley D ^a   Dickerson, Scott H ^a   Dickson, Hamilton D ^a   Emerson, Holly K ^a   Griffin, Robert J ^a   Hubbard, Robert D ^a   Keith, Barry R ^a   Mullin, Robert J ^a   Petrov, Kimberly G ^a   Gerding, Roseanne M ^a   Reno, Michael J ^a   Rheault, Tara R ^a   Rusnak, David W ^a   Sammond, Douglas M ^a   Smith, Stephon C ^a   Uehling, David E ^a   Waterson, Alex G ^a   Wood, Edgar R ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; ErbB 2; Inhibitor; Proline; Thieno 3,2 d pyrimidines

Indexed keywords

CARBAMIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PYRROLIDINYLACETYLENIC THIENO[3,2 D]PYRIMIDINE DERIVATIVE; THIENO[3,2 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; MICE; PHARMACOKINETICS; PYRIMIDINES; PYRROLIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749096199     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.023     Document Type: Article

References (23)

1. Seymour L.K. Curr. Drug Targets 2 (2001) 117
2. Yarden Y. Eur. J. Cancer 37 (2001) S3
3. Rowinsky E.K. Annu. Rev. Med. 55 (2004) 433
4. Dumas J. Curr. Opin. Drug Discov. Dev. 4 (2001) 378
5. Baker A.J., Gibson K.H., Grudy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., and Richards L. Bioorg. Med. Chem. Lett. 11 (2001) 1191
6. Bonomi P. Expert Rev. Anticancer Ther. 3 (2003) 367
7. Rusnak D.W., Lackey K.E., Wood E.R., Alligood K.J., Rhodes N., Knight W.B., and Gilmer T.M. Mol. Cancer Ther. 1 (2001) 85
8. Allen L.F., Eiseman I.A., Fry D.W., and Lenehan P.F. Semin. Oncol. 30 (2003) 65
9. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.-R., Wang Y.-F., and Wissner A. Cancer Res. 64 (2004) 3958
10. Reid A., Vidal L., Shaw H., and de Bono J. Eur. J. Cancer 433 (2007) 481
11. Fry D.W. Anti-Cancer Drug Des. 15 (2000) 3
12. Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., Caferro T.R., Dickerson S.D., Dickson H.D., Donaldson K.H., Gaul M., Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., Waterson A.G., Williams J.D., White W.L., and Uehling D.E. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2773
13. Waterson, A. G.; Petrov, K. G.; Hornberger, K. R.; Hubbard, R. D.; Sammond, D. M.; Smith, S. C.; Hinkle, K. W.; Stevens, K. L.; Uehling, D. E.; Dickerson, S. H.; Rusnak, D. W.; Spehar, G. M.; Wood, E. R.; Griffin, R. J. Bioorg. Med. Chem. Lett., submitted for publication.
14. Hubbard R.D., Dickerson S.H., Emerson H.K., Griffin R.J., Reno M.J., Hornberger K.R., Rusnak D.W., Wood E.R., Uehling D.E., and Waterson A.G. Bioorg. Med. Chem. Lett. 18 (2008) 5738
15. Trybulski E.J., Kramss R.H., Mangano R.M., and Rusinko A. J. Med. Chem. 33 (1990) 3190
16. Compound 4 (CAS#: 225385-03-5) has recently become commercially available through Medinoah Inc., Wallingford, CT. Synthetic details can be found in PCT Int. Appl. WO 99/24440. Compound 5 is prepared by displacement on the chloro of 4 with 3-chloro-4-(3-fluorobenzyloxy)aniline which is available through Affinitis Pharma LLC, New Haven, CT. Synthetic details can be found in PCT Int. Appl. WO 98/02437.
17. The modification data was only acquired for EGFR using methods described in Ref. 12. These analogs have not been assayed versus ErbB-2 for potential reactivity.
18. Thienopyrimidine analogs (6a-j) were found to be selective for the transformed cell lines (HN5 and BT474) versus a control human foreskin fibroblast cell line (HFF). Experimental protocols are described in Ref. 7.
19. Ohira S. Synth. Commun. 19 (1989) 561
20. Dickson H.D., Smith S.C., and Hinkle K.W. Tetrahedron Lett. 45 (2004) 5597
21. (4R)-4-Hydroxy-(2R)-proline 5g, $153; (4S)-4-Hydroxy-(2R)-proline 5g, $291, both from AstaTech, Bristol, PA. Advanced derivatives of the 2-(S) enantiomer, such as 10, are occasionally available, 5g, $169 from AstraTech.
22. Baker G.L., Fritschel S.J., Stille J.R., and Stille J.K. J. Org. Chem. 46 (1981) 2954
23. Dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA), see:. Braunwalder A.F., Yarwood D.R., Sills M.A., and Lipson K.E. Anal. Biochem. 238 (1996) 159 BT474 cells and their culture conditions are described in Ref. 7